CClinicalTrials.gg
RecruitingNCT05052736Updated Aug 28, 2025

Non Invasive Neurostimulation Technology for the Treatment of Type I Complex Regional Pain Syndrome (CRPS I)

An interventional study of Non-invasive Neuromodulation in Type I Complex Regional Pain Syndrome, sponsored by University of Las Palmas de Gran Canaria. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by University of Las Palmas de Gran Canaria · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Complex Regional Pain Syndrome (CRPS) / Complex Regional Pain Syndrome (CRPS) is a chronic neurological disorder that affects the extremities and is characterized by disabling pain, swelling, vasomotor instability, sudomotor abnormality, and impaired motor function; the duration and clinical magnitude is greater than expected, being divided into three stages of progression over time: Stage I: acute (0-3 months); Stage II: dystrophic (3-9 months); Stage 3: atrophic (9-18 months).

The purpose of this study is to investigate the effect on complex pain syndrome using a conventional care protocol plus the application of non-invasive neuromodulation during compared to the effect of the same protocol plus placebo.

Read the detailed description

The design of this study is a randomised, triple blind clinical trial with placebo control.

The size of the sample will be 42 participants who come to referral hospitals. They will be randomized in two groups: control or experimental.

The variables of the study will be collected at three time points: before the intervention, during the intervention and at the end of the intervention.

The variables of the study will be collected at two time points: before the intervention and at the end of the intervention.

The statistical analysis will be an intention-to-treat analysis. For the main outcomes variables a two factor ANOVA will-be performed (intervention-time) with a post-hoc analysis with kruskal wallis correction correction. Statistical significance will be defined as p \<0.05

02

Conditions studied

  • Type I Complex Regional Pain Syndrome

Keywords

  • physical therapy modality
  • Electric Stimulation Therapy
  • pain
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Meet the Budapest criteria for the clinical diagnosis of CRPS type I.
  • Age between 18 and 65.
  • Period between 0 and 6 months after the onset of the clinical picture.
  • Have signed the informed consent of their own free will.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of CRPS type II.
  • Present type I CRPS in more than one limb.
  • Patients who have suffered a recurrence of CRPS type I.
  • Pregnancy or plans for it during the study.
  • Previous sympathectomy in the affected limb.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Non-invasive Neuromodulation

    Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.

    Device: Non-invasive Neuromodulation

  • Placebo comparator
    Placebo Non-invasive Neuromodulation

    Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.

    Device: Non-invasive Neuromodulation

Interventions

  • DeviceNon-invasive Neuromodulation

    The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.

05

What researchers measure

Primary outcomes

  1. Pain ( VAS)

    The instrument will be used to measure the change of pain before and after the intervention will be the Visual Analogue Scale (VAS). Participants will be asked to mark the level of their pain on a 100 mm, no hatched VAS scale marked at one end as "no pain" and at the other as "worst pain imaginable".

    Time frame: Up to 6 month

  2. Quick Dash Test

    The Quick DASH Upper Extremity Rating Scale for Upper Extremity can be completed by the patient in aid of the orthopedic surgeon. It consists of 11 items that assess the presence of symptoms and the functional capacity of the individual surveyed during the last week. A total of 11 questions must be answered for the questionnaire to calculate the functional situation accurately

    Time frame: Up to 6 month

Secondary outcomes

  1. Muscle balance

    The Daniels scale or Daniels test is a tool used to measure the strength of muscles in the human body, especially in patients with neuromuscular disorders or localized injuries. the scale itself follows a specific numbering, with six well-differentiated levels from 0 to 5. These are the following: 0: the muscle does not contract, complete paralysis. 1. the muscle contracts, but there is no movement. The contraction can be palpated or visualized, but there is no movement. 2. the muscle contracts and performs all the movement, but without resistance, since it cannot overcome gravity. 3. the muscle can carry out the movement against gravity as the only resistance. 4. the muscle contracts and performs the full movement, in full range, against gravity and against moderate manual resistance. 5. the muscle contracts and performs the movement in full range against gravity and with maximum manual resistance

    Time frame: Up to 6 month

  2. Sleep quality

    The Medical Outcomes Study Sleep Scale questionnaire will be used. This instrument was designed to obtain subjective information on the quality and quantity of sleep in the last 4 weeks. It is composed of 12 Likert-type items with 6 degrees of response (from 1-always to 6-never) and grouped into the following categories: * Sleep disturbances * snoring * Waking up with shortness of breath or headache * Amount of sleep * Adequacy of sleep * Daytime sleepiness For its interpretation, a gross estimate of the amount of sleep is obtained (item 2) and scores in the different subscales. The direct scores are transformed into a scale from 0 to 100, with no cut-off points; the higher the score, the greater the intensity of the concept evaluated.

    Time frame: Up to 6 month

06

Study locations

1 of 1 sites recruiting
  • Aníbal Báez Suárez
    Las Palmas de Gran Canaria, Palmas, Las 35016, Spain
    • Aníbal Báez Suárez, PhD · Contact · anibal.baez@ulpgc.es · 652077692
    • Roque González Díez, PhD · Principal investigator
    • Eloisa Navarro Gonzalez, PhD · Sub investigator
    • Pilar Loscos Gil, PhD · Sub investigator
    • Raquel Medina Ramirez, PhD · Sub investigator
    Recruiting
07

References and documents

Publications

  • Sebastin SJ. Complex regional pain syndrome. Indian J Plast Surg. 2011 May;44(2):298-307. doi: 10.4103/0970-0358.85351. PubMed 22022040 ↗
  • Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome--diagnostic, mechanisms, CNS involvement and therapy. Spinal Cord. 2003 Feb;41(2):61-75. doi: 10.1038/sj.sc.3101404. PubMed 12595868 ↗
  • Todorova J, Dantchev N, Petrova G. Complex regional pain syndrome acceptance and the alternative denominations in the medical literature. Med Princ Pract. 2013;22(3):295-300. doi: 10.1159/000343905. Epub 2012 Nov 16. PubMed 23171669 ↗
  • Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010 Sep;113(3):713-25. doi: 10.1097/ALN.0b013e3181e3db38. PubMed 20693883 ↗
  • Ratti C, Nordio A, Resmini G, Murena L. Post-traumatic complex regional pain syndrome: clinical features and epidemiology. Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(Suppl 1):11-6. doi: 10.11138/ccmbm/2015.12.3s.011. Epub 2016 Apr 7. PubMed 27134626 ↗
  • Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain. 2003 May;103(1-2):199-207. doi: 10.1016/s0304-3959(03)00065-4. PubMed 12749974 ↗
  • Elsamadicy AA, Yang S, Sergesketter AR, Ashraf B, Charalambous L, Kemeny H, Ejikeme T, Ren X, Pagadala P, Parente B, Xie J, Lad SP. Prevalence and Cost Analysis of Complex Regional Pain Syndrome (CRPS): A Role for Neuromodulation. Neuromodulation. 2018 Jul;21(5):423-430. doi: 10.1111/ner.12691. Epub 2017 Sep 29. PubMed 28961359 ↗
  • Albazaz R, Wong YT, Homer-Vanniasinkam S. Complex regional pain syndrome: a review. Ann Vasc Surg. 2008 Mar;22(2):297-306. doi: 10.1016/j.avsg.2007.10.006. PubMed 18346583 ↗
08

Registry details

Key details

Study ID
NCT05052736
Lead sponsor
University of Las Palmas de Gran Canaria
Responsible party
Aníbal Báez Suárez (Principal Investigator, University of Las Palmas de Gran Canaria) — Principal investigator
First posted
Sep 22, 2021
Start date
Mar 28, 2022
Primary completion
Apr 27, 2026 (estimated)
Completion
Dec 27, 2026 (estimated)
Last update
Aug 28, 2025

Study contacts

Aníbal Báez-Suárez, PhD
Contact
anibal.baez@ulpgc.es
+34 652077692
Aníbal Báez-Suárez, PhD
Contact
anibal.baez@ulpgc.es
+34652077692
Aníbal Báez-Suárez, PhD
principal investigator · University of Las Palmas de Gran Canaria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion